Regeneron Pharmaceuticals, Inc. (REGN) Q1 2021 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.37%

Regeneron's strong EPS performance, exceeding expectations by over 27%, has positively impacted investor sentiment, resulting in a 3.37% increase in stock price. The company did not provide revenue figures or guidance, leaving some uncertainty for investors. However, the focus on advancing their product pipeline suggests potential for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$9.89	N/A	+27.12%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the strong EPS results, highlighting their commitment to innovation. They emphasized the importance of maintaining access to their products for patients.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline and ensuring patient access to our therapies.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.37%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.37%

Key numbers

Management commentary